Background/Aims The influence of hepatic steatosis (HS) on chronic hepatitis B (CHB) is
unclear. We evaluated the influence of the degree of HS, assessed using the controlled …

ABSTRACT Background/Aims: We aimed to evaluate the impact of non-alcoholic fatty liver
disease (NAFLD) on viral kinetics and virologic response to tenofovir and entecavir …

Background & Aims The interaction between chronic hepatitis B (CHB) and hepatic steatosis
is poorly understood. We investigated whether measurement of controlled attenuation …

Background The coexistence of HBV infection and nonalcoholic fatty liver disease (NAFLD)
becomes characteristic of liver disease in China, with unknown bilateral influence. We …

Abstract Background/Aims Regression of liver fibrosis during antiviral therapy in chronic
hepatitis B (CHB) patients has been demonstrated, but data on the influence of long-term …

Background & aims Nonalcoholic fatty liver disease (NAFLD) and chronic hepatitis B (CHB)
are common liver diseases. Concurrent NAFLD may affect antiviral treatment outcomes in …

Abstract Background & Aims Liver stiffness (LS) measurement using transient elastography
allows for accurate evaluation of liver fibrosis in patients with chronic liver disease. We …

Long‐term suppression of hepatitis B virus with tenofovir (TDF) induces fibrosis regression,
and repeated liver stiffness (LS) measurement can indicate the improvement of fibrosis. We …

Background & Aims Concomitant non-alcoholic fatty liver disease is common in patients with
chronic hepatitis B (CHB) infection, although its impact on liver-related outcomes remains …

Background Concomitant chronic hepatitis B infection (CHB) and non-alcoholic fatty liver
disease (NAFLD) is common, but the implications of NAFLD on clinical outcomes of CHB …